How India Exports Theophylline to the World

In the United States, Theophylline is approved for use in various formulations, including extended-release tablets. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for Theophylline products, indicating a competitive generic market. Notably, on June 3, 2021, the FDA approved Glenmark Pharmaceuticals Inc.'s ANDA for Theophylline Extended-Release Tablets in 300 mg and 450 mg strengths.

The importation of Theophylline into the U.S. requires compliance with FDA regulations, including adherence to Current Good Manufacturing Practices (cGMP) and successful completion of the ANDA process. Given that 46.5% of India's Theophylline exports are directed to the U.S., Indian manufacturers must ensure rigorous compliance with these standards to maintain market access.

In the European Union, Theophylline-containing medicinal products require marketing authorization from the European Medicines Agency (EMA) or national competent authorities. Manufacturers must comply with the EU's Good Manufacturing Practice (GMP) guidelines to ensure product quality and safety. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization and regulation of medicinal products, including Theophylline.

Theophylline is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in treating respiratory conditions. This inclusion facilitates its availability and accessibility in various healthcare systems worldwide. Additionally, Theophylline formulations are standardized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, Theophylline is classified as a Schedule H drug under the Drugs and Cosmetics Rules, 1945, indicating that it is available only by prescription. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including Theophylline, to ensure affordability. Manufacturers intending to export Theophylline must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with export regulations.

Theophylline is an established drug with no active patents, allowing for widespread generic competition. This has led to a competitive market landscape, with multiple manufacturers producing and exporting Theophylline formulations.

In June 2021, the FDA approved Glenmark Pharmaceuticals Inc.'s ANDA for Theophylline Extended-Release Tablets, 300 mg and 450 mg, enhancing the availability of generic Theophylline products in the U.S. market.

In March 2025, the Veterinary Medicines Directorate (VMD) in the UK revised the product information for Corvental-D Hard Capsules containing Theophylline 100 mg, indicating ongoing regulatory oversight and updates to ensure product safety and efficacy. (vmd.defra.gov.uk)

These developments reflect the dynamic nature of the pharmaceutical industry and the importance of staying abreast of regulatory changes and market approvals to maintain compliance and competitiveness in the global Theophylline market.

India's pharmaceutical industry, including the production of Theophylline, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these critical components are sourced from China, underscoring a significant dependency. This reliance exposes the supply chain to vulnerabilities, particularly during geopolitical tensions or trade disruptions.

Efforts to mitigate this dependency have been initiated through the Production Linked Incentive (PLI) scheme, aiming to bolster domestic production of APIs and KSMs. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, marking a step towards reducing import reliance. However, the transition to self-sufficiency is gradual, and the industry remains susceptible to external supply shocks in the interim.

The export market for Theophylline from India is notably concentrated, with the top five exporters—Alembic Pharmaceuticals Limited, Adcock Ingram Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, and Mancare Pharmaceuticals Private Limited—accounting for 70.3% of total exports. Alembic Pharmaceuticals Limited alone holds a 23.8% share. Such concentration poses a single-source risk; any operational disruptions within these key companies could significantly impact global supply.

The PLI scheme, launched to enhance domestic API and KSM production, aims to diversify the supplier base and reduce dependency on a limited number of exporters. While this initiative is promising, its full impact on mitigating supplier concentration risks will materialize over time.

Recent geopolitical events have severely disrupted global supply chains. In March 2026, the closure of the Strait of Hormuz amid escalating conflicts led to significant delays and increased shipping costs. This chokepoint is vital for global trade, and its obstruction has had cascading effects on industries reliant on timely deliveries, including pharmaceuticals.

Additionally, tensions in the Red Sea and the Strait of Hormuz have compounded these challenges. The pharmaceutical industry, dependent on these routes for the transport of APIs and finished products, faces heightened risks of supply chain disruptions, leading to potential shortages and increased costs. (lemonde.fr)

• Diversify API and KSM Sources: Accelerate efforts to develop alternative sources for APIs and KSMs, both domestically and from other countries, to reduce reliance on a single nation.

• Enhance Supplier Base: Encourage the growth of smaller and mid-sized pharmaceutical exporters to distribute market share more evenly and mitigate single-source risks.

• Strengthen Domestic Manufacturing: Invest in infrastructure and technology to bolster domestic production capabilities for critical pharmaceutical components.

• Develop Contingency Logistics Plans: Establish alternative shipping routes and logistics strategies to navigate around geopolitical hotspots and ensure continuity in supply chains.

• Monitor Geopolitical Developments: Implement robust monitoring systems to stay informed about geopolitical events that could impact supply chains, enabling proactive risk management.

RISK_LEVEL: HIGH